No Data
No Data
Acumen Pharmaceuticals Files for $200M Mixed Shelf Offering
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcript
HC Wainwright & Co. Maintains Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
HC Wainwright & Co. analyst Andrew Fein maintains Acumen Pharmaceuticals with a Buy and maintains $15 price target.
Acumen Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 301.07% HC Wainwright & Co. $15 → $15 Maintains Buy 12/12/2023 113.9% Deutsche Bank → $8 Initia
Buy Rating Affirmed for Acumen Pharmaceuticals Amid Promising Alzheimer's Treatment Development and Attractive Valuation
Q4 2023 Acumen Pharmaceuticals Inc Earnings Call
No Data